SPHRF Starpharma Holdings Limited
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1/2 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Note: This is not a U.S. company, but they cross-list their shares on the U.S. over-the-counter market - see the related symbol AT:SPL.
$0.32 OTCQX
As of 03/23/2023 OTCMarkets
Security Information
Category1: US Equity
Category2: Common stocks
Category3: Micro cap
GICS sector: Health Care
Industry: Biotechnology
Index country: Australia
Country of incorporation:
IPO date: 04/05/2002
Outstanding shares: 409,259,777
Average volume: 9
Market cap: $129,694,423
Current dividend yield: 0.00%
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%